CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 66 of the 168 sources its claims cite were checked for support.

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Open access
Haahr, Hanne, Heise, Tim · 2014 · Clinical Pharmacokinetics

Abstract

Data show that insulin degludec has a half-life of >25 h and reaches steady state within 3 days of administration. The pharmacokinetic profile demonstrates an even distribution of exposure across one dosing interval.

Overview

CoChat Summary

## TL;DR

This review summarizes pharmacological studies of insulin degludec (IDeg) and argues that its ultra-long, flat profile and lower day-to-day variability may translate into more flexible dosing and less hypoglycaemia. The paper reports a half-life of >25 h, steady state within 3 days, duration of action beyond 42 h, and four-times lower within-subject variability than insulin glargine.

## Key findings

  • IDeg forms multi-hexamers after subcutaneous injection, creating a soluble depot from which insulin is slowly and continuously absorbed; in contrast, insulin glargine forms microprecipitates that must re-dissolve before absorption.
  • In pharmacokinetic studies, IDeg reached clinical steady state within 3 days, had a half-life of >25 h, and showed evenly distributed exposure across a 24 h dosing interval.
  • In pharmacodynamic studies, IDeg had a flat, stable glucose-lowering effect across 24 h and an ultra-long duration of action exceeding 42 h in subjects with type 1 diabetes; in type 2 diabetes, duration of action was beyond 26 h.
  • In a randomized double-blind crossover trial in type 1 diabetes, within-subject variability in glucose-lowering effect was four-times lower with IDeg than with insulin glargine (CV 20% vs 82%; p < 0.0001), and the projected risk of more than double the usual maximum effect was <0.1% for IDeg vs 11% for glargine.

## Methods

  • Narrative review of pharmacokinetic and pharmacodynamic studies of IDeg, drawing on multiple clinical trials and phase III data; the paper states the BEGIN clinical trial programme included over 11,000 patients in more than 40 countries.
  • Across studies, data collection was standardized: blood sampling for pharmacokinetic endpoints and euglycaemic clamp procedures for pharmacodynamic endpoints, with mostly steady-state designs and limited study centers to reduce variability.
  • Main analyses included concentration–time profiles, glucose infusion rate outcomes from clamp studies, linear mixed models on log-transformed pharmacodynamic endpoints, and comparisons/meta-analysis versus insulin glargine.

## Limitations

  • The paper states that most studies used steady-state conditions, but some special-population studies used single-dose designs and simulated steady-state profiles instead, which may limit direct comparability across all settings.
  • The review notes that IDeg had not yet been approved in the USA at the time, and that cardiovascular safety concerns from FDA review were still being addressed in an ongoing outcomes trial (DEVOTE); this indicates the clinical safety picture was still incomplete.
  • Evident from the text: this is a review article summarizing published studies rather than a new primary study, so its conclusions depend on the design and populations of the underlying trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40262-014-0165-y

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Conceptual model demonstrating action profiles with once-daily dosing of a basal insulin with duration of action a ≤24 h and b substantially longer than 24 h [14]
Fig. 1 Conceptual model demonstrating action profiles with once-daily dosing of a basal insulin with duration of action a ≤24 h and b substantially longer than 24 h [14]CC BY-NC · PubMed Central
Fig. 2 Mechanism of protraction of insulin degludec (IDeg) and visualisation of IDeg using electron microscopy. a Schematic representation of the formation of IDeg multi-hexamers in the subcutaneous depot from di-hexamers in the pharmaceutical formulation [adapted from Jonassen et al. [16] (Fig. 5, p. 2,112), with kind permission from Springer Science + Business Media). b A transmission electron microscope image showing the effect of phenol on IDeg multi-hexamer linkage—the figure depicts elongated IDeg structures in the absence of phenol; the scale bar represents 200 nm (adapted and reprinted with permission from Steensgaard et al. [18]; Copyright 2014 American Chemical Society)
Fig. 2 Mechanism of protraction of insulin degludec (IDeg) and visualisation of IDeg using electron microscopy. a Schematic representation of the formation of IDeg multi-hexamers in the subcutaneous depot from di-hexamers in the pharmaceutical formulation [adapted from Jonassen et al. [16] (Fig. 5, p. 2,112), with kind permission from Springer Science + Business Media). b A transmission electron microscope image showing the effect of phenol on IDeg multi-hexamer linkage—the figure depicts elongated IDeg structures in the absence of phenol; the scale bar represents 200 nm (adapted and reprinted with permission from Steensgaard et al. [18]; Copyright 2014 American Chemical Society)CC BY-NC · PubMed Central
Fig. 3 Concentration–time profiles of insulin degludec 100 U/mL (IDeg U100) dosed at 0.4 U/kg in subjects with a type 1 diabetes mellitus [34] or b type 2 diabetes (data taken from Heise et al. [21]). Also shown are the concentration–time profiles for c IDeg U100 and IDeg 200 U/mL (IDeg U200) dosed at 0.4 U/kg in subjects with type 1 diabetes [reproduced from Korsatko et al. [20], Fig. 2a, p. 518], with kind permission from Springer Science + Business Media)
Fig. 3 Concentration–time profiles of insulin degludec 100 U/mL (IDeg U100) dosed at 0.4 U/kg in subjects with a type 1 diabetes mellitus [34] or b type 2 diabetes (data taken from Heise et al. [21]). Also shown are the concentration–time profiles for c IDeg U100 and IDeg 200 U/mL (IDeg U200) dosed at 0.4 U/kg in subjects with type 1 diabetes [reproduced from Korsatko et al. [20], Fig. 2a, p. 518], with kind permission from Springer Science + Business Media)CC BY-NC · PubMed Central
Fig. 4 Glucose infusion rate profiles with insulin degludec (IDeg) for subjects with a type 1 diabetes mellitus [23], b type 2 diabetes (reproduced from Heise et al. [21], with permission from John Wiley and Sons, Inc.) and c different race or ethnic backgrounds with type 2 diabetes (reprinted from Hompesch et al. [25], with permission from Elsevier)
Fig. 4 Glucose infusion rate profiles with insulin degludec (IDeg) for subjects with a type 1 diabetes mellitus [23], b type 2 diabetes (reproduced from Heise et al. [21], with permission from John Wiley and Sons, Inc.) and c different race or ethnic backgrounds with type 2 diabetes (reprinted from Hompesch et al. [25], with permission from Elsevier)CC BY-NC · PubMed Central
Fig. 5 Duration of action of insulin degludec (IDeg) as indicated by the duration of blood glucose control during glucose clamp experiments in subjects with a type 1 diabetes mellitus (0.6 U/kg) [15] or b type 2 diabetes (reproduced from Heise et al. [21], with permission from John Wiley and Sons, Inc.)
Fig. 5 Duration of action of insulin degludec (IDeg) as indicated by the duration of blood glucose control during glucose clamp experiments in subjects with a type 1 diabetes mellitus (0.6 U/kg) [15] or b type 2 diabetes (reproduced from Heise et al. [21], with permission from John Wiley and Sons, Inc.)CC BY-NC · PubMed Central
Fig. 6 Subject-specific day-to-day variability in the area under the glucose infusion rate curve for insulin degludec (IDeg) or insulin glargine (IGlar) dosed at 0.4 U/kg during one dosing interval (0–24 h) at steady state (reproduced from Heise et al. [22], with permission from John Wiley and Sons, Inc.). CV coefficient of variation
Fig. 6 Subject-specific day-to-day variability in the area under the glucose infusion rate curve for insulin degludec (IDeg) or insulin glargine (IGlar) dosed at 0.4 U/kg during one dosing interval (0–24 h) at steady state (reproduced from Heise et al. [22], with permission from John Wiley and Sons, Inc.). CV coefficient of variationCC BY-NC · PubMed Central
Fig. 7 Day-to-day variability in glucose-lowering effect of insulin degludec (IDeg) and insulin glargine (IGlar) dosed at 0.4 U/kg over 24 h at steady state (reproduced from Heise et al. [22], with permission from John Wiley and Sons, Inc.). AUC GIR area under the glucose infusion rate profile, CV coefficient of variation
Fig. 7 Day-to-day variability in glucose-lowering effect of insulin degludec (IDeg) and insulin glargine (IGlar) dosed at 0.4 U/kg over 24 h at steady state (reproduced from Heise et al. [22], with permission from John Wiley and Sons, Inc.). AUC GIR area under the glucose infusion rate profile, CV coefficient of variationCC BY-NC · PubMed Central
Fig. 8 Simulated insulin degludec (IDeg) concentration–time profiles at steady state in smaller children (1–5 years), children (6–11 years), adolescents (12–17 years) and adults (18–65 years) over a 24-h dosing interval. The simulation was made using the final model from a joint analysis of the pharmacokinetic data from a single-dose trial with IDeg in children, adolescents and adults with type 1 diabetes mellitus (N = 36) [29] and steady-state population pharmacokinetic data obtained over 26 weeks in a clinical trial with IDeg in children and adolescents with type 1 diabetes (N = 169) [40]. The profiles shown are (median) for a typical subject in each age group [with body weight (BW) equal to the median BW in that age group]
Fig. 8 Simulated insulin degludec (IDeg) concentration–time profiles at steady state in smaller children (1–5 years), children (6–11 years), adolescents (12–17 years) and adults (18–65 years) over a 24-h dosing interval. The simulation was made using the final model from a joint analysis of the pharmacokinetic data from a single-dose trial with IDeg in children, adolescents and adults with type 1 diabetes mellitus (N = 36) [29] and steady-state population pharmacokinetic data obtained over 26 weeks in a clinical trial with IDeg in children and adolescents with type 1 diabetes (N = 169) [40]. The profiles shown are (median) for a typical subject in each age group [with body weight (BW) equal to the median BW in that age group]CC BY-NC · PubMed Central

Verification

Claims the paper makes

47 Valid · 2 Not valid · 58 Not checked · 26 Own results and interpretations

76 more claims · 26 with their cited sources checked

Create a free account to see all 133 claims and to verify the 21 references still open.

See all claims — free account
  • It may state two separate claims as one. 38
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Citations

Cites

Show all 57 references

Research works printed but not linked: 5

  1. Dhatariya K, Yeong J. Improved glycaemic controls for patients on twice daily dosing regime of insulin glargine compared to those on a once daily dosing regime. Diabetologia. 2010;53(suppl 1):S390.
  2. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54(suppl 1):S426.
  3. Haahr H, Ikushima I, Hirao K, et al. Similar pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese and Caucasian subjects with T1DM [abstract no. PCS-16-6]. J Diabetes Investig. 2012;3(suppl s1):197.
  4. Leiter L, Yale JF, Chaisson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on hypoglycemia management and glucose control management. Can J Diabetes. 2005;29:186–92.
  5. Oyer DS, Heller S, Gough SCL, et al. Exercise-related hypoglycaemia occurs at similar frequency with insulin degludec and insulin glargine [abstract]. Diabetologia. 2013;56(suppl 1):S84.

Cited by

See all 226

Metadata

Authors
Haahr, H., & Heise, T.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • Profil Institute for Metabolic Research (DE)
Corresponding author
Haahr, Hanne
Venue
Clinical Pharmacokinetics
Published
2014-09
Volume
53
Issue
9
Pages
787-800
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2034327086
Cited by
226
References
57
Citations by year
2026: 8 · 2025: 10 · 2024: 15 · 2023: 14 · 2022: 20 · 2021: 21 · 2020: 23 · 2019: 27 · 2018: 24 · 2017: 26 · 2016: 20 · 2015: 17 · 2014: 1
FWCI
3.39
Type
journal article
Language
en
Open access
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
insulin degludec, basal insulin, pharmacokinetics, pharmacodynamics, insulin glargine, glucose-lowering effect, euglycaemic clamp, type 1 diabetes, type 2 diabetes, liver dysfunction, renal dysfunction, elderly patients, ethnic differences
MeSH terms
Chemistry, Pharmaceutical, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. https://app.cochat.ai/papers/10.1007/s40262-014-0165-y
The paper
Haahr, H., & Heise, T. (2014). A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-014-0165-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.